Topoisomerase-specific drug sensitivity in relation to cell cycle progression

Area of Science:

• Molecular Biology
• Cell Biology
• Biochemistry

Background:

• DNA topoisomerase II is a nuclear enzyme critical for DNA replication, transcription, and repair.
• It mediates the DNA cleavage and cytotoxicity of anticancer drugs like etoposide.
• Understanding topoisomerase II activity during the cell cycle is vital for cancer therapy.

Purpose of the Study:

• To investigate the activity of topoisomerase II during the initial cell cycle of quiescent BALB/c 3T3 cells after serum stimulation.
• To correlate topoisomerase II activity with etoposide sensitivity and cytotoxicity.
• To determine the role of protein synthesis in regulating topoisomerase II activity.

Main Methods:

• Assaying etoposide-mediated DNA break frequency in vivo as a measure of topoisomerase II activity.
• Quantifying intracellular topoisomerase II content using immunoblotting.
• Utilizing protein synthesis inhibitor (cycloheximide) and DNA synthesis inhibitor (aphidicolin) to assess regulatory mechanisms.

Main Results:

• Quiescent cells showed increased etoposide sensitivity upon serum stimulation, peaking before mitosis.
• This heightened sensitivity correlated with increased intracellular topoisomerase II levels.
• Inhibition of protein synthesis abolished the induction of drug sensitivity, while DNA synthesis inhibition had no effect.
• Maximal cytotoxicity occurred during S phase, distinct from peak DNA cleavage activity.

Conclusions:

• Topoisomerase II activity fluctuates with cell cycle progression, with peak activity in G2 phase.
• The increase in topoisomerase II is dependent on protein synthesis, suggesting high enzyme turnover.
• Topoisomerase II-mediated DNA breaks are necessary but not sufficient for cytotoxicity, with other S-phase factors playing a role.